Skip to main content
Erschienen in:

01.12.2014 | Multiple Myeloma (R Niesvizky, Section Editor)

What We Mean When We Talk About MRD in Myeloma. A Review of Current Methods. Part 1 of a Two-Part Series

verfasst von: Scott Ely, Noa Biran, Ajai Chari

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Assessment of minimal residual disease (MRD) is becoming standard of care for potentially curable cancers, like some leukemias. For diseases not currently curable, like multiple myeloma (MM), the optimal methodology to assess MRD is much less clear, let alone the clinical significance. In this two-part series, we review each of these aspects of MRD in MM. In part 1, we review different methodologies available for MRD assessment, with an emphasis on multiparameter flow cytometry (MFC) and duplex immunohistochemistry. There is currently a strong push in the MM community for the use of MFC, based on studies demonstrating MRD negativity by MFC being associated with delayed time to relapse. After participating in a recent international meeting of leaders in the field, convened to discuss this topic, we review and assess the voiced opinions and published data. While great strides have been made toward the standardization of MFC for MRD, we review not only intrinsic biologic differences between MM and leukemia but also the technical challenges that follow from these differences, including the need for live cells, a difficult to characterize immunophenotype, and significant interlaboratory variability in MFC testing and interpretation.
Literatur
1.
Zurück zum Zitat Polzer B, Klein CA. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat Med. 2013;19(3):274–5.PubMedCrossRef Polzer B, Klein CA. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat Med. 2013;19(3):274–5.PubMedCrossRef
2.
Zurück zum Zitat Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999;17(1):208–15.PubMed Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999;17(1):208–15.PubMed
3.
Zurück zum Zitat Cavo M, Terragna C, Martinelli G, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96(1):355–7.PubMed Cavo M, Terragna C, Martinelli G, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96(1):355–7.PubMed
4.
Zurück zum Zitat Martinelli G, Terragna C, Zamagni E, et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica. 2000;85(9):930–4.PubMed Martinelli G, Terragna C, Zamagni E, et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica. 2000;85(9):930–4.PubMed
5.
Zurück zum Zitat Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2000;18(11):2273–81. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2000;18(11):2273–81.
6.
Zurück zum Zitat Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112(3):814–9.PubMedCrossRef Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112(3):814–9.PubMedCrossRef
7.
Zurück zum Zitat Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX study. J Clin Oncol. 2013;31(20):2540–7.PubMedCrossRef Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX study. J Clin Oncol. 2013;31(20):2540–7.PubMedCrossRef
8.
Zurück zum Zitat Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant. 2012;18(12):1790–9.PubMedCrossRef Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant. 2012;18(12):1790–9.PubMedCrossRef
9.
Zurück zum Zitat Biran N, Ely S, Chari A. Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques. Curr Hematol Malig Rep. 2014. doi:10.1007/s11899-014-0237-y Biran N, Ely S, Chari A. Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques. Curr Hematol Malig Rep. 2014. doi:10.​1007/​s11899-014-0237-y
10.
Zurück zum Zitat Hartmann L, Biggerstaff JS, Chapman DB, et al. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques. Am J Clin Pathol. 2011;136(5):712–20.PubMedCrossRef Hartmann L, Biggerstaff JS, Chapman DB, et al. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques. Am J Clin Pathol. 2011;136(5):712–20.PubMedCrossRef
11.
Zurück zum Zitat Liat Nadav B-ZK, Shoshana B, Lydia Y, Aaron P, Varda D, Benjamin G, et al. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol. 2006;133(5):530–2.PubMedCrossRef Liat Nadav B-ZK, Shoshana B, Lydia Y, Aaron P, Varda D, Benjamin G, et al. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol. 2006;133(5):530–2.PubMedCrossRef
12.
Zurück zum Zitat Paiva B, Vidriales M-B, Pérez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Vol. 94; 2009. Paiva B, Vidriales M-B, Pérez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Vol. 94; 2009.
13.
Zurück zum Zitat Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028(1):390–9.PubMedCrossRef Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028(1):390–9.PubMedCrossRef
14.
Zurück zum Zitat Colombo M, Mirandola L, Platonova N, et al. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia. 2013;27(5):1009–18.PubMedCrossRef Colombo M, Mirandola L, Platonova N, et al. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia. 2013;27(5):1009–18.PubMedCrossRef
15.
Zurück zum Zitat Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663–9.PubMedCentralPubMedCrossRef Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663–9.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–53.PubMed Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–53.PubMed
17.
Zurück zum Zitat Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Journal of clinical oncology. 2011. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Journal of clinical oncology. 2011.
18.
Zurück zum Zitat Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18):2514–20.PubMedCentralPubMedCrossRef Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18):2514–20.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Zhen C, Wang YL. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013;15(5):556–64.PubMedCrossRef Zhen C, Wang YL. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013;15(5):556–64.PubMedCrossRef
20.
Zurück zum Zitat Soverini S, Rosti G, Baccarani M, Martinelli G. Molecular monitoring. Curr Hematol Malignancy Rep. 2014;9(1):1–8.CrossRef Soverini S, Rosti G, Baccarani M, Martinelli G. Molecular monitoring. Curr Hematol Malignancy Rep. 2014;9(1):1–8.CrossRef
21.
Zurück zum Zitat Ely S, Kroft, SH, Reichard, KK, Orazi, A., Foucar, K., Knowles, D., Weiss, L.M. Knowles Neoplastic hematopathology: Wolters Kluwer Health; 2013. Ely S, Kroft, SH, Reichard, KK, Orazi, A., Foucar, K., Knowles, D., Weiss, L.M. Knowles Neoplastic hematopathology: Wolters Kluwer Health; 2013.
22.
Zurück zum Zitat Sailer M, Vykoupil KF, Peest D, Coldewey R, Deicher H, Georgii A. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol. 1995;54(3):137–46.PubMedCrossRef Sailer M, Vykoupil KF, Peest D, Coldewey R, Deicher H, Georgii A. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol. 1995;54(3):137–46.PubMedCrossRef
23.
Zurück zum Zitat Sukpanichnant S, Cousar JB, Leelasiri A, Graber SE, Greer JP, Collins RD. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol. 1994;25(3):308–18.PubMedCrossRef Sukpanichnant S, Cousar JB, Leelasiri A, Graber SE, Greer JP, Collins RD. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol. 1994;25(3):308–18.PubMedCrossRef
24.
Zurück zum Zitat Frassanito MA, Rao L, Moschetta M, et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia. 2014;28(4):904–16.PubMedCrossRef Frassanito MA, Rao L, Moschetta M, et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia. 2014;28(4):904–16.PubMedCrossRef
25.
Zurück zum Zitat Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160(4):1293–9.PubMedCentralPubMedCrossRef Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160(4):1293–9.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Terpstra WE, Lokhorst HM, Blomjous F, Meuwissen OJ, Dekker AW. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol. 1992;82(1):46–9.PubMedCrossRef Terpstra WE, Lokhorst HM, Blomjous F, Meuwissen OJ, Dekker AW. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol. 1992;82(1):46–9.PubMedCrossRef
27.
Zurück zum Zitat Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol. 2008;61(2):213–6.PubMedCrossRef Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol. 2008;61(2):213–6.PubMedCrossRef
28.
Zurück zum Zitat Ng A, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Vol. 91; 2006. Ng A, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Vol. 91; 2006.
29.
Zurück zum Zitat Ely S. Using aspirates for multiple myeloma research probably excludes important data. Br J Haematol. 2006;134(2):245–6.PubMedCrossRef Ely S. Using aspirates for multiple myeloma research probably excludes important data. Br J Haematol. 2006;134(2):245–6.PubMedCrossRef
30.
Zurück zum Zitat Durie BG. US Myeloma Flow Workshop in New York. Myeloma voices, international myeloma foundation: international myeloma foundation; 2014. Durie BG. US Myeloma Flow Workshop in New York. Myeloma voices, international myeloma foundation: international myeloma foundation; 2014.
31.
Zurück zum Zitat Ahmann GJ, Chng WJ, Henderson KJ, et al. Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomark Prev. 2008;17(3):666–73.CrossRef Ahmann GJ, Chng WJ, Henderson KJ, et al. Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomark Prev. 2008;17(3):666–73.CrossRef
32.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, (Eds.). WHO classification of tumours of haematopoietic and lymphoid tissues Lyon, France: International Agency for Research on Cancer; 2008. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, (Eds.). WHO classification of tumours of haematopoietic and lymphoid tissues Lyon, France: International Agency for Research on Cancer; 2008.
33.
Zurück zum Zitat Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Cancer Netw. 2009;7(9):908–42. Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Cancer Netw. 2009;7(9):908–42.
34.
Zurück zum Zitat Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med. 1993;178(3):1023–31.PubMedCrossRef Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med. 1993;178(3):1023–31.PubMedCrossRef
35.
Zurück zum Zitat Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Vol. 122; 2013. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Vol. 122; 2013.
36.
Zurück zum Zitat Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O. Minimal residual disease: what are the minimum requirements? J Clin Oncol. 2014;32(5):475–6.PubMedCrossRef Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O. Minimal residual disease: what are the minimum requirements? J Clin Oncol. 2014;32(5):475–6.PubMedCrossRef
37.
Zurück zum Zitat Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38(3):371–6.PubMedCrossRef Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38(3):371–6.PubMedCrossRef
38.
Zurück zum Zitat Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365–72.PubMed Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365–72.PubMed
39.
Zurück zum Zitat Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008.
40.
Zurück zum Zitat Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612–24.PubMedCrossRef Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612–24.PubMedCrossRef
41.
Zurück zum Zitat Paiva B, Martinez-Lopez J, Vidriales M-B, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. Journal of clinical oncology. 2011. Paiva B, Martinez-Lopez J, Vidriales M-B, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. Journal of clinical oncology. 2011.
42.
Zurück zum Zitat Paiva B, Gutiérrez NC, Rosiñol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Vol. 119; 2012. Paiva B, Gutiérrez NC, Rosiñol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Vol. 119; 2012.
43.
Zurück zum Zitat Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100(4):637–46.PubMedCrossRef Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100(4):637–46.PubMedCrossRef
44.
Zurück zum Zitat Ramani VC, Sanderson RD. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol. 2014;35:215–22.PubMedCrossRef Ramani VC, Sanderson RD. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol. 2014;35:215–22.PubMedCrossRef
45.
Zurück zum Zitat van Dongen JJM, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–75.PubMedCentralPubMedCrossRef van Dongen JJM, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–75.PubMedCentralPubMedCrossRef
46.
Zurück zum Zitat Mark T, Jayabalan D, Coleman M, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008. Mark T, Jayabalan D, Coleman M, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008.
47.
Zurück zum Zitat Kim HS, Kim HS, Shin KS, et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. Biomed Res Int. 2014;2014:647238.PubMedCentralPubMed Kim HS, Kim HS, Shin KS, et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. Biomed Res Int. 2014;2014:647238.PubMedCentralPubMed
48.
Zurück zum Zitat Kraj M. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite) assays for diagnosing and monitoring monoclonal gammopathies. Adv Clin Exp Med. 2014;23(1):127–33.PubMed Kraj M. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite) assays for diagnosing and monitoring monoclonal gammopathies. Adv Clin Exp Med. 2014;23(1):127–33.PubMed
49.
Zurück zum Zitat Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.PubMedCentralPubMedCrossRef Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma. 2012;53(4):641–7.PubMedCrossRef Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma. 2012;53(4):641–7.PubMedCrossRef
51.
Zurück zum Zitat Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–9.PubMedCentralPubMedCrossRef Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–9.PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat Paiva B, Paino T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–8.PubMedCrossRef Paiva B, Paino T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–8.PubMedCrossRef
53.
Zurück zum Zitat Frisch B, Bartl R. Biopsy interpretation of bone and bone marrow: histology and immunohistology in paraffin and plastic: Arnold; 1999. Frisch B, Bartl R. Biopsy interpretation of bone and bone marrow: histology and immunohistology in paraffin and plastic: Arnold; 1999.
54.
Zurück zum Zitat Wei A, Westerman D, Feleppa F, Trivett M, Juneja S. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica. 2005;90(8):1147–9.PubMed Wei A, Westerman D, Feleppa F, Trivett M, Juneja S. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica. 2005;90(8):1147–9.PubMed
55.
Zurück zum Zitat Zhao X, Huang Q, Slovak M, Weiss L. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol. 2006;125(6):895–904.PubMedCrossRef Zhao X, Huang Q, Slovak M, Weiss L. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol. 2006;125(6):895–904.PubMedCrossRef
56.
Zurück zum Zitat Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Vol. 106; 2005. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Vol. 106; 2005.
57.
Zurück zum Zitat Jungbluth AA, Ely S, DiLiberto M, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106(1):167–74.PubMedCrossRef Jungbluth AA, Ely S, DiLiberto M, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106(1):167–74.PubMedCrossRef
Metadaten
Titel
What We Mean When We Talk About MRD in Myeloma. A Review of Current Methods. Part 1 of a Two-Part Series
verfasst von
Scott Ely
Noa Biran
Ajai Chari
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2014
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-014-0238-x

Weitere Artikel der Ausgabe 4/2014

Back to Biology: New Insights on Inheritance in Myeloproliferative Disorders

  • Myeloproliferative Disorders (C Harrison, Section Editor)

An Immune Dysregulation in MPN

  • Myeloproliferative Disorders (C Harrison, Section Editor)

Resuscitating a Dying Marrow: the Role of Hematopoietic Growth Factors

  • Myelodysplastic Syndromes (M Sekeres, Section Editor)

Controversies in Multiple Myeloma: to Transplant or Not?

  • Multiple Myeloma (R Niesvizky, Section Editor)

Lessons from the Atomic Bomb About Secondary MDS

  • Myelodysplastic Syndromes (M Sekeres, Section Editor)

Quality of Life in MPN Comes of Age as a Therapeutic Target

  • Myeloproliferative Disorders (C Harrison, Section Editor)

Neu im Fachgebiet Onkologie

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.